850424-10-1 Usage
General Description
2(1H)-Quinazolinone, 6-methoxy is a chemical compound with the molecular formula C10H9N3O2. It is a derivative of quinazolinone, which is a heterocyclic compound that is commonly found in pharmaceutical drugs and natural products. The 6-methoxy substitution on the quinazolinone ring gives the compound unique chemical and biological properties. It is used as a building block in the synthesis of various biologically active molecules and pharmaceutical drugs. Additionally, 2(1H)-Quinazolinone, 6-methoxy has been studied for its potential pharmacological activities, including its effects on the central nervous system, antitumor properties, and anti-inflammatory activity. Overall, 2(1H)-Quinazolinone, 6-methoxy has potential applications in drug discovery and development due to its diverse biological activities and chemical reactivity.
Check Digit Verification of cas no
The CAS Registry Mumber 850424-10-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,0,4,2 and 4 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 850424-10:
(8*8)+(7*5)+(6*0)+(5*4)+(4*2)+(3*4)+(2*1)+(1*0)=141
141 % 10 = 1
So 850424-10-1 is a valid CAS Registry Number.
850424-10-1Relevant articles and documents
Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors
Ramurthy, Savithri,Costales, Abran,Jansen, Johanna M.,Levine, Barry,Renhowe, Paul A.,Shafer, Cynthia M.,Subramanian, Sharadha
, p. 1678 - 1681 (2012/04/04)
Compounds belonging to several scaffolds-quinazolines, quinolines and quinoxalines-were designed and synthesized as Raf kinase inhibitors. Scaffolds were assessed for in vitro BrafV600E inhibition, and overall kinase selectivity. Pharmacokinetic parameters for one of the scaffolds were also determined.
2,6-Disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of RAF kinase
-
Page/Page column 14; 18, (2010/02/11)
New substituted quinazoline, quinoxaline, quinoline and isoquinoline compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
